Genetically Targeted Fractionated Chemotherapy
Aaron J. Smith, John Oertle, Dino Prato*
Envita, Scottsdale, USA.
DOI: 10.4236/jct.2015.62021   PDF    HTML   XML   4,669 Downloads   8,839 Views   Citations


Complex and late stage cancer patients are in need of novel methods of selecting and administering chemotherapy particularly for those patients who are refractory to current treatment methods. The use of biomarkers to enhance decision making with regard to the molecular profile of a person’s cancer is becoming more important in the practice of oncology. The standard for the last several decades is to elect chemotherapeutic agents based on staging and histological identification of the primary cancer site alone versus utilizing the genetic and molecular profile information along with histological primary cancer site and staging to select chemotherapy regimens. Cancers are caused by mutations that occur within cells and therefore selecting treatment based on mutations and not primary cancer site alone can provide advantages that may have gone overlooked. As time progresses, more biomarkers continue to be discovered which can lead to more targets for drugs either currently on the market or clinical trials. In addition to advancements made in the progression of cancer treatment with utilizing molecular profiles effectively, there are other therapeutic strategies that have been postulated as advanced effective ways to administer chemotherapy. These strategies provide chemotherapy to patients while fasting, giving insulin or other biological response modifiers adjunctively prior to chemotherapy for enhanced targeting, and giving chemotherapy in micro-doses to allow for increased frequency of administration and the utilization of multiple targeted chemotherapeutic agents concurrently. In this paper we will discuss these topics and explain their benefits in addition to the evidence that supports these treatments. A review on biomarkers and cancer cell metabolism is discussed as it relates to providing a framework for what constitutes a biomarker in addition to what metabolic processes are related to fasting and administering insulin with chemotherapy. The information provided in this document is designed to illuminate and provide evidence for various methodologies that are underserved in the treatment of cancer.

Share and Cite:

Smith, A. , Oertle, J. and Prato, D. (2015) Genetically Targeted Fractionated Chemotherapy. Journal of Cancer Therapy, 6, 182-198. doi: 10.4236/jct.2015.62021.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Weeks, J.C., Catalano, P.J., Cronin, A., Finkelman, M.D., Mack, J.W., Keating, N.L. and Schrag, D. (2012) Pateints’ Expectation about Effects of Chemotherapy for Advanced Cancer. The New England Journal of Medicine, 367, 1616-1625.
[2] Srinivas, P.R., Kramer, B.S. and Srivastava, S. (2001) Trends in Biomarker Research for Cancer Detection. The Lancet Oncology, 2, 698-704.
[3] Cho, W.S.C. (2007) Contribution of Oncoproteomics to Cancer Biomarker Discovery. Molecular Cancer, 6, 25.
[4] Hanahan, D. and Weinberg, R.A. (2000) The Hallmarks of Cancer. Cell, 100, 57-70.
[5] Ludwig, J.A. and John, N. (2005) Weinstein Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nature Reviews Cancer, 5, 845-856.
[6] Egger, G., Liang, G., Aparicio, A. and Jones, P.A. (2004) Epigenetics in Human Disease and Prospects for Epigenetic Therapy. Nature, 429, 457-463.
[7] Cristofanilli, M., Budd, G.T., Ellis, M.J., Stopeck, A., Matera, J., Miller, M.C., et al. (2005) Presence of Circulating Tumor Cells (CTC) in Metastatic Breast Cancer (MBC) Predicts Rapid Progression and Poor Prognosis. Journal of Clinical Oncology, 23, 524.
[8] Liyanage, U.K., Moore, T.T., Joo, H.-G., Tanaka, Y., Herrmann, V., Doherty, G., et al. (2002) Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma. Journal of Immunology, 169, 2756-2761.
[9] Siddiqui, S.A., Frigola, X., Bonne-Annee, S., Mercader, M., Kuntz, S.M., Krambeck, A.E., et al. (2007) Tumor-Infiltrating Foxp3–CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma. Clinical Cancer Research, 13, 2075-2081.
[10] Woo, E.Y., Yeh, H., Chu, C.S., Schlienger, K., Carroll, R.G., Riley, J.L., et al. (2002) Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation. Journal of Immunology, 168, 4272-4276.
[11] Wolf, A.M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E. and Grubeck-Loebenstein, B. (2003) Increase of Regulatory T Cells in the Peripheral Blood of Cancer Patients. Clinical Cancer Research, 9, 606-612.
[12] Viguier, M., Lema?tre, F., Verola, O., Cho, M.S., Gorochov, G., Dubertret, L., et al. (2004) Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells. Journal of Immunology, 173, 1444-1453.
[13] Ormandy, L.A., Hillemann, T., Wedemeyer, H., Manns, M.P., Greten, T.F. and Korangy, F. (2005) Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma. Cancer Research, 65, 2457-1464.
[14] Joosten, S.A. and Ottenhoff, T.H.M. (2008) Human CD4 and CD8 Regulatory T Cells in Infectious Diseases and Vaccination. Human Immunology, 69, 760-770.
[15] Bishop, J.M. (1987) The Molecular Genetics of Cancer. Science, 235, 305-311.
[16] Whitfield, M.L., George, L.K., Grant, G.D. and Perou, C.M. (2006) Common Markers of Proliferation. Nature Reviews Cancer, 6, 99-106.
[17] Dunning, A.M., Healey, C.S., Pharoah, P.D.P., Teare, D.M., Ponder, B.A.J. and Easton, D.F. (1999) A Systematic Review of Genetic Polymorphisms and Breast Cancer Risk. Cancer Epidemiology, Biomarkers & Prevention, 8, 843-854.
[18] Toru, H., Masaharu, Y., Shinji, T. and Kazuaki, C. (2008) Genetic Polymorphisms and Head and Neck Cancer Risk. International Journal of Oncology, 32, 945-973.
[19] Ignatiadis, M., Xenidis, N., Perraki, M., Apostolaki, S., Politaki, E., Kafousi, M., et al. (2007) Different Prognostic Value of Cytokeratin-19 mRNA Positive Circulating Tumor Cells According to Estrogen Receptor and HER2 Status in Early-Stage Breast Cancer. Journal of Clinical Oncology, 25, 5194-5202.
[20] Delys, L., Detours, V., Franc, B., Thomas, G., Bogdanova, T., Tronko, M., et al. (2007) Gene Expression and the Biological Phenotype of Papillary Thyroid Carcinomas. Oncogene, 26, 7894-7903.
[21] Dwarakanath, B.S., Manogaran, P.S., Das, S., Das, B.S. and Jain, V. (1994) Heterogeneity in DNA Content and Proliferative Status of Human Brain Tumors. Indian Journal of Medical Research, 100, 279-286.
[22] Weber, J.L. and May, P.E. (1989) Abundant Class of Human DNA Polymorphisms Which Can Be Typed Using Polymerase Chain Reaction. American Journal of Human Genetics, 44, 388-396.
[23] Arzimanoglou, I.I., Gilbert, F. and Barger, H.R. (1998) Microsatellite Instability in Human Solid Tumors. Cancer, 82, 1808-1820.<1808::AID-CNCR2>3.0.CO;2-J
[24] Arnold, K. (2000) Biomarker for Esophageal Cancer Found in Bloodstream. Journal of the National Cancer Institute, 92, 1787.
[25] Fearnhead, N.S., Britton, M.P. and Bodmer, W.F. (2001) The ABC of APC. Human Molecular Genetics, 10, 721-733.
[26] Kim, H., Kwon, Y.M., Kim, J.S., Lee, H., Park, J.H., Shim, Y.M., et al. (2004) Tumor-Specific Methylation in Bronchial Lavage for the Early Detection of Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22, 2363-2370.
[27] Ehrlich, M. (2002) DNA Methylation in Cancer: Too Much, but Also Too Little. Oncogene, 21, 5400-5413.
[28] Cuezva, J.M., Krajewska, M., Heredia, M.L., Krajewski, S., Kim, G.S.H., Zapata, J.M., et al. (2002) The Bioenergetic Signature of Cancer: A Marker of Tumor Progression. Cancer Research, 62, 6674-6681.
[29] Reivich, M., Kuhl, D., Wolf, A., Greenberg, J., Phelps, M., Ido, T., et al. (1977) Measurement of Local Cerebral Glucose Metabolism in Man with 18F-2-Fluoro-2-deoxy-D-glucose. Acta neurologica Scandinavica. Supplementum, 64, 190-191.
[30] Dichiro, G., Brooks, R.A., Patronas, N.T., Bairamian, D., Kornblith, P.L., Smith, B.H., et al. (1984) Issues in the in Vivo Measurement of Glucose Metabolism of Human Central Nervous System Tumors. Annals of Neurology, 15, 138-146.
[31] Padma, M.V., Said, S., Jacobs, M., Hwang, D.R., Dunigan, K., Satter, M., et al. (2003) Prediction of Pathology and Survival by FDG PET in Gliomas. Journal of Neuro-Oncology, 64, 227-237.
[32] Spence, A.M., Muzi, M., Graham, M.M., O’Sullivan, F., Link, J.M., Lewellen, T.K., et al. (2002) 2-[18F]Fluoro-2-deoxyglucose and Glucose Uptake in Malignant Gliomas before and after Radiotherapy: Correlation with Outcome. Clinical Cancer Research, 8, 971-979.
[33] Weber, W.A. (2006) Positron Emission Tomography as an Imaging Biomarker. Journal of Clinical Oncology, 20, 3282-3292.
[34] Stricker, T., Vatenacci, D.V.T. and Seiwert, T.Y. (2011) Molecular Profiling of Cancer—The Future of Personalized Cancer Medicine: A Primer on Cancer Biology and the Tools Necessary to Bring Molecular Testing to the Clinic. Seminars in Oncology, 38, 173-185.
[35] Thurlimann, B., Goldhirsch, A., Castiglione, M., Hsu-Schmitz, S.F., Cavalli, F., Bonnefoi, H., et al. (1997) Formestane versus Megestrol Acetate in Postmenopausal Breast Cancer Patients after Failure of Tamoxifen: A Phase III Prospective Randomised Cross over Trial of Second-Line Hormonal Treatment (SAKK 20/90). European Journal of Cancer, 33, 1017-1024.
[36] Stuart, N.S.A., Warwick, J., Blackledge, G.R.P., Spooner, D., Keen, C., Earl, H., et al. (1996) A Randomized Phase III Cross-Over Study of Tamoxifen versus Megestrol Acetate in Advanced and Recurrent Breast Cancer. European Journal of Cancer, 32, 1888-1892.
[37] Cuzick, J. (2007) LHRH-Agonists in Early Breast Cancer Overview Group. Use of Luteinising-Hormone-Releasing Hormone Agonists as Adjuvant Treatment in Premenopausal Patients with Hormone-Receptor-Positive Breast Cancer: A Meta-Analysis of Individual Patient Data from Randomised Adjuvant Trials. The Lancet, 369, 1711-1723.
[38] Lewis, J.D., Chagpar, A.B., Shaughnessy, E.A., Nurko, J., McMasters, K. and Edwards, M.J. (2010) Excellent Outcomes with Adjuvant Toremifene or Tamoxifen in Early Stage Breast Cancer. Cancer, 116, 2307-2315.
[39] Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Allred, C., et al. (2008) Relationship between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status with Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. Journal of Clinical Oncology, 26, 1059-1065.
[40] Bartlett, J.M.S., Rea, D., et al. (2011) Estrogen Receptor and Progesterone Receptor as Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology, 29, 1531-1538.
[41] Coombes, R.C., Kilburn, L.S., Snowdon, C.F., Paridaens, R., Coleman, R.E., Bliss, J.M., et al. (2007) Survival and Safety of Exemestane versus Tamoxifen after 2-3 Years’ Tamoxifen Treatment (Intergroup Exemestane Study): A Randomized Controlled Trial. The Lancet, 369, 559-570.
[42] Viale, G., Regan, M.M., Maiorano, E., Mastropasqua, M.G., Golouh, R., Regan, M.M., et al. (2008) Chemoendocrine Compared with Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study Group. Journal of Clinical Oncology, 26, 1404-1410.
[43] Anderson, H., Hills, M., Zabaglo, L., A’Hern, R., Leary, A.F., Dowsett, M., et al. (2011) Relationship between Estrogen Receptor, Progesterone Receptor, HER-2 and Ki67 Expression and Efficacy of Aromatase Inhibitors in Advanced Breast Cancer. Annals of Oncology, 22, 1770-1776.
[44] Stendahl, M., Ryden, L., Nordenskjold, B., Ebbe J?nsson, P., Landberg, G. and Jirstrom, K. (2006) High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients. Clinical Cancer Research, 12, 4614-4618.
[45] Yamashita, H., Ando, Y., Nishio, M., Zhang, Z., Hamaguchi, M., Mita, K., et al. (2006) Immunohisto- chemical Evaluation of Hormone Receptor Status for Predicting Response to Endocrine Therapy in Metastatic Breast Cancer. Breast Cancer, 13, 74-83.
[46] Yu, Z., Yang, Q., et al. (2005) Thymidylate Synthase Predicts for Clinical Outcome in Invasive Breast Cancer. Histology and Histopathology, 20, 871-878.
[47] Chen, C.Y., Yang, P.C., et al. (2011) Thymidylate Synthase and Dihydrofolate Reductase Expression in Non-Small Cell Lung Carcinoma: The Association with Treatment Efficacy of Pemetrexed. Lung Cancer, 74, 132-138.
[48] Lee, S.J., Im, Y.H., et al. (2011) Thymidylate Synthase and Thymidine Phosphorylase as Predictive Markers of Capecitabine Monotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. Cancer Chemotherapy and Pharmacology, 68, 743-751.
[49] Penson, R.T., Seiden, M.V., et al. (2004) Expression of Multidrug Resistance-1 Protein Inversely Correlates with Paclitaxel Response and Survival in Ovarian Cancer Patients: A Study in Serial Samples. Gynecologic Oncology, 93, 98-106.
[50] Yeh, J.J., Hsu, W.H., Wang, J.J., Ho, S.T. and Kao, A. (2003) Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer with P-Glycoprotein Expression. Respiration, 70, 32-35.
[51] Von Hoff, D.D., Hidalgo, M., et al. (2011) Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients with Advanced Pancreatic Cancer: A Phase I/II Trial. Journal of Clinical Oncology, 29, 4548-4554.
[52] Desai, N., Trieu, V., Damascelli, B. and Soon-Shiong, P. (2009) SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. Translational Oncology, 2, 59-64.
[53] Seve, P., Dumontet, C., et al. (2005) Class III β-Tubulin Expression in Tumor Cells Predicts Response and Outcome in Patients with Non-Small Cell Lung Cancer Receiving Paclitaxel. Molecular Cancer Therapeutics, 4, 2001-2007.
[54] Ploussard, G., de la Taille, A., et al. (2010) Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy. Clinical Cancer Research, 70, 9253-9264.
[55] Gao, S., Zhao, X., Lin, B., Hu, Z., Yan, L. and Gao, J. (2012) Clinical Implications of REST and TUBB3 in Ovarian Cancer and Its Relationship to Paclitaxel Resistance. Tumor Biology, 33, 1759-1765.
[56] Zhang, H.L., Ruan, L., Zheng, L-M., Whyte, D., Tzeng, C-M. and Zhou, X.W. (2012) Association between Class III β-Tubulin Expression and Response to Paclitaxel/Vinorelbine-Based Chemotherapy for Non-Small Cell Lung Cancer: A Meta-Analysis. Lung Cancer, 77, 9-15.
[57] Kulkarni, S.A., Ross, D.T., et al. (2009) TLE3 as a Candidate Biomarker of Response to Taxane Therapy. Breast Cancer Research, 11, R17.
[58] Gong, W., Dong, J., et al. (2012) RRM1 Expression and Clinical Outcome of Gemcitabine-Containing Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. Lung Cancer, 75, 374-380.
[59] Ataka, M., Katano, K., et al. (2007) Topoisomerase I Protein Expression and Prognosis of Patients with Colorectal Cancer. Yonago Acta Medica, 50, 81-87.
[60] Braun, M.S., Seymour, M.T., et al. (2008) Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results from the UK MRC FOCUS Trial. Journal of Clinical Oncology, 26, 2690-2698.
[61] Kostopoulos, I., Fountzilas, G., et al. (2009) Topoisomerase I but Not Thymidylate Synthase Is Associated with Improved Outcome in Patients with Resected Colorectal Cancer Treated with Irinotecan Containing Adjuvant Chemotherapy. BMC Cancer, 9, 339.
[62] Baselga, J., Swain, S.M., et al. (2012) Pertuzumab Plus Trastumab Plus Docetaxel for Metastatic Breast Cancer. The New England Journal of Medicine, 36, 109-119.
[63] National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 2.2013.
[64] Bachelot, T., Pujade-Lauraine, E., et al. (2012) Randomized Phase II Trial of Everolimus in Combination with Tamoxifen in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors: A GINECO Study. Journal of Clinical Oncology, 30, 2718-2724
[65] Wolff, A.C., Hayes, D.F., et al. (2013) Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 31, 3997-4013.
[66] Janku, F., Kurzrock, R., et al. (2012) PI3K/AKT/mTOR Inhibitors in Patients with Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. Journal of Clinical Oncology, 30, 777-782.
[67] Janku, F., Kurzrock, R., et al. (2012) PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials. Cancer Research, 73, 276-284.
[68] Moroney, J.W., Kurzrock, R., et al. (2011) A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies. Clinical Cancer Research, 17, 6840-6846.
[69] Guo, J., Qin, S., et al. (2011) Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients with Metastatic Melanoma Harboring c-Kit Mutation or Amplification. Journal of Clinical Oncology, 29, 2904-2909.
[70] Carvajal, R.D., Schwartz, G.K., et al. (2011) KIT as a Therapeutic Target in Metastatic Melanoma. Journal of the American Medical Association, 305, 2327-2334.
[71] Debiec-Rychter, M., Judson, I., et al. (2006) KIT Mutations and Dose Selection for Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours. European Journal of Cancer, 42, 1093-1103.
[72] Heinrich, M.C., Fletcher, J.A., et al. (2008) Correlation of Kinase Genotype and Clinical Outcome in North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Journal of Clinical Oncology, 26, 5360-5367.
[73] Cassier, P.A., Hohenberger, P., et al. (2012) Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. Clinical Cancer Research, 18, 4458-4464.
[74] Wells, S.A., Schlumberger, M.J., et al. (2012) Vandetanib in Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology, 30, 134-141.
[75] Gennari, A., Bruzzi, P., et al. (2008) HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials. Journal of the National Cancer Institute, 100, 14-20.
[76] Press, M.F., Slamon, D.J., et al. (2011) Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association with Responsiveness to Anthracycline Based Chemotherapy. Journal of Clinical Oncology, 29, 859-867.
[77] Akimoto, M., Saisho, H., et al. (2006) Relationship between Therapeutic Efficacy of Arterial Infusion Chemotherapy and Expression of P-Glycoprotein and p53 Protein in Advanced Hepatocellular Carcinoma. World Journal of Gastroenterology, 12, 868-873.
[78] Mittal, M.K., Singh, J.P., et al. (2005) Role of p-Glycoprotein Expression in Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer—A Prospective Clinical Study. World Journal of Surgical Oncology, 3, 61.
[79] O’Malley, F.P., Pritchard, K.I., et al. (2011) Topoisomerase II Alpha Protein and Responsiveness of Breast Cancer to Adjuvant Chemotherapy with CEF Compared to CMF in the NCIC CTG Randomized MA.5 Adjuvant Trial. Breast Cancer Research and Treatment, 128, 401-409.
[80] Rodrigo, R.S., Axel L.C., et al. (2011) Topoisomerase II-Alpha Protein Expression and Histological Response Following Doxorubicin-Based Induction Chemotherapy Predict Survival of Locally Advanced Soft Tissues Sarcomas. European Journal of Cancer, 47, 1319-1327.
[81] Buckingham, L.P., Bonomi, P., et al. (2007) The Prognostic Value of Chromosome 7 Polysomy in Non-Small Cell Lung Cancer Patients Treated with Gefitinib. Journal of Thoracic Oncology, 2, 414-422.
[82] Verma, S., Blackwell, K., et al. (2012) Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. The New England Journal of Medicine, 367, 1783-1791.
[83] Cortes, J., Baselga, J., et al. (2012) Pertuzumab Monotherapy after Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients with Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Clinical Oncology, 30, 1594-1600.
[84] Bang, Y.J., Kang, Y.K., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697.
[85] Yin, W., Jiang, Y., Shen, Z., Shao, Z. and Lu, J. (2011) Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials. PLoS ONE, 6, e21030.
[86] Slamon, D., Buyse, M., et al. (2011) Adjuvant Trastuzumab in HER2-Positive Breast Cancer. The New England Journal of Medicine, 365, 1273-1283.
[87] Hurvitz, S.A., Perez, E.A., et al. (2013) Phase II Randomized Study of Trastuzumab Emtansine versus Trastuzumab plus Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 31, 1157-1163.
[88] Johnston, S., Pegram, M., et al. (2009) Lapatinib Combined with Letrozole versus Letrozole and Placebo as First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 27, 5538-5546.
[89] Amir, E., Oca?a, A., Seruga, B., Freedman, O. and Clemons, M. (2010) Lapatinib and HER2 Status: Results of a Meta-Analysis of Randomized Phase III Trials in Metastatic Breast Cancer. Cancer Treatment Reviews, 36, 410-415.
[90] Press, M.F., Finn, R.S., et al. (2008) HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer. Clinical Cancer Research, 14, 7861-7870.
[91] Chinot, O.L., Barrie, M., et al. (2007) Correlation between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated with Neoadjuvant Temozolomide. Journal of Clinical Oncology, 25, 1470-1475.
[92] Busch, C., Geislerd, J., Lillehaug, J.R. and Lonning, P.E. (2010) MGMT Expression Levels Predict Disease Stabilisation, Progression-Free and Overall Survival in Patients with Advanced Melanomas Treated with DTIC. European Journal of Cancer, 46, 2127-2133.
[93] Warburg, O. (1923) Metabolism of Tumours. Biochemische Zeitschrift, 142, 317-333.
[94] Warburg, O. (1925) Iron, the Oxygen-Carrier of Respiration-Ferment. Science, 61, 575-582.
[95] Racker, E. (1972) Bioenergetics and the Problem of Tumor Growth. American Scientist, 60, 56-63.
[96] Turner, J.S. and Brittain, E.G. (1962) Oxygen as a Factor in Photosynthesis. Biological Reviews, 37, 130-170.
[97] Lee, C., Raffaghello, L., Brandhorst, S., Safdie, F.M., Bianchi, G., Martin-Montalvo, A., Pistoia, V., Wei, M., Hwang, S., Merlino, A., Emionite, L., Cabo, R. and Longo, V. (2012) Fasting Cycles Retard Growth of Tumor and Sensitize a Range of Cancer Cell Types to Chemotherapy. Science Translational Medicine, 4, 124-127.
[98] Cushman, S.W. and Wardzala, L.J. (1980) Potential Mechanism of Insulin Action on Glucose Transport in the Isolated Rat Adipose Cell. Apparent Translocation of Intracellular Transport Systems to the Plasma Membrane. Journal of Biological Chemistry, 255, 4758-4762.
[99] Suzuki, K. and Kono, T. (1980) Evidence That Insulin Causes Translocation of Glucose Transport Activity to the Plasma Membrane from an Intracellular Storage Site. Proceedings of the National Academy of Sciences of the United States of America, 77, 2542-2545.
[100] Papa, V., Pezzino, V., Costantino, A., Belfiore, A., Giuffrida, D., Frittitta, L., Vannelli, G.B., Brand, R., Goldfine, I.D. and Vigneri, R. (1990) Elevated Insulin Receptor Content in Human Breast Cancer. Journal of Clinical Investigation, 86, 1503-1510.
[101] Belfiore, A. (2007) The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer. Current Pharmaceutical Design, 13, 671-686.
[102] Grana, X. and Reddy, E.P. (1995) Cell Cycle Control in Mammalian Cells: Role of Cyclins, Cyclin Dependent Kinases (CDKs), Growth Suppressor Genes and Cyclin-Dependent Kinase Inhibitors (CKIs). Oncogene, 11, 211-219.
[103] Johnson, D.G. and Walker, C.L. (1999) Cyclins and Cell Cycle Checkpoints. Annual Review of Pharmacology and Toxicology, 39, 295-312.
[104] Kaldis, P., Russo, A.A., Chou, H.S., Pavletich, N.P. and Solomon, M.J. (1998) Human and Yeast Cdk-Activating Kinases (CAKs) Display Distinct Substrate Specificities. Molecular Biology of the Cell, 9, 2545-2560.
[105] Hartwell, L.H. and Kastan, M.B. (1994) Cell Cycle Control and Cancer. Science, 266, 1821-1828.
[106] Harper, J. and Elledge, S.J. (1996) Cdk Inhibitors in Development and Cancer. Current Opinion in Genetics & Development, 6, 56-64.
[107] Senderowicz, A.M. (2002) Cyclin-Dependent Kinases as Targets for Cancer Therapy. In: Giaccone, G., Schilsky, R. and Sondel. P., Eds., Cancer Chemotherapy and Biological Response Modifiers Annual 20, Elsevier Science, New York, 169-188.
[108] Gliozzo, B., Sung, C.K., Scalia, P.L., Papa, V., Frasca, F., Sciacca, L., Giorgino, F., Milazzo, G., Goldfine, I.D., Vigneri, R. and Pezzino, V.J. (1998) Insulin-Stimulated Cell Growth in Insulin Receptor Substrate-1-Deficient ZR-75-1 Cells Is Mediated by a Phosphatidylinositol-3-Kinase-Independent Pathway. Journal of Cellular Biochemistry, 70, 268-280.<268::AID-JCB12>3.0.CO;2-J
[109] Bentel, J.M., Lebwohl, D.E., Cullen, K.J., Rubin, M.S., Rosen, N., Mendelsohn, J. and Miller, W.H. (1995) Insulin-Like Growth Factors Modulate the Growth Inhibitory Effects of Retinoic Acid on MCF-7 Breast Cancer Cells. Journal of Cellular Physiology, 165, 212-221.
[110] Yang, X.F., Beamer, W.G., Huynh, H.T. and Pollak, M. (1996) Cancer Research, 56, 1509-1511.
[111] Pollak, M., Constantino, J., Polychronakos, C., Blauer, S.A., Guyda, H., Redmond, C., Fisher, B. and Margolese, R. (1990) Effect of Tamoxifen on Serum Insulinlike Growth Factor I Levels in Stage I Breast Cancer Patients. Journal of the National Cancer Institute, 82, 1693-1697.
[112] Milazzo, G., Giorgino, F., Damante, G., Sung, C., Stampfer, M.R., Vigneri, R., Goldfine, I. and Belfiore, A. (1992) Cancer Research, 52, 3924-3930.
[113] Frittitta, L., Vigneri, R., Stampfer, M.R. and Goldfine, I.D.J. (1995) Insulin Receptor Overexpression in 184B5 Human Mammary Epithelial Cells Induces a Ligand-Dependent Transformed Phenotype. Journal of Cellular Biochemistry, 57, 666-669.
[114] Kaleko, M., Rutter, W.J. and Miller, A.D. (1990) Molecular and Cellular Biology, 10, 464-473.
[115] Mountjoy, K.G., Finlay, G.J. and Holdaway, I.M. (1987) Cancer Research, 47, 6500-6504.
[116] Benson, E.A. and Holdaway, I.M. (1982) Cancer Research, 42, 1137-1141.
[117] Belfiore, A., Frittitta, L., Costantino, A., Frasca, F., Pandini, G., Sciacca, L., Goldfine, I.D. and Vigneri, R. (1996) Insulin Receptors in Breast Cancer. Annals of the New York Academy of Sciences, 784, 173-188.
[118] Chappell, J., Leitner, W., Solomon, S., Golovchenko, I., Goalstone, M.L. and Draznin, B. (2001) Effect of Insulin on Cell Cycle Progression in MCF-7 Breast Cancer Cells. Journal of Biological Chemistry, 41, 38023-38028.
[119] Reyman, P. (1997) Chemotherapy Principles of Administration. In: Groenwald, S.L., Yarbro, C.H., Goodman, M. and Frogge, M.H., Eds., Cancer Nursing Principles and Practice, 4th Edition.
[120] Dorr, R.T. and Vonn Hoff, D.D. (1993) Cancer Chemotherapy Handbook. 2nd Edition. Appleton & Lange, Norwalk.
[121] Schilsky, R.L., Bailey, B.D. and Chabner, B.A. (1981) Characteristics of Membrane Transport of Methotrexate by Cultured Human Breast Cancer Cells. Biochemical Pharmacology, 30, 1537-1542.
[122] Lippman, M., Bolan, G. and Huff, K. (1976) The Effects of Estrogens and Antiestrogens on Hormone-Responsive Human Breast Cancer in Long-Term Tissue Culture. Cancer Research, 36, 4595-4601.
[123] Monaco, M.E. and Lippman, M.E. (1977) Insulin Stimulation of Fatty Acid Synthesis in Human Breast Cancer in Long Term Tissue Culture. Endocrinology, 101, 1238-1246.
[124] Plich, P.F., Thompson, P.A. and Czech, M.P. (1980) Coordinate Modulation of D-Glucose Transport Activity and Bilayer Fluidity in Plasma Membranes Derived from Control and Insulin-Treated Adipocytes. Proceedings of the National Academy of Sciences of the United States of America, 77, 915-918.
[125] Snyder, A.L., Kann, H.E. and Kohn, K.W. (1971) Inhibition of the Processing of Ribosomal Precursor RNA by Intercalating Agents. Journal of Molecular Biology, 58, 555-565.
[126] Tobey, R.A. (1972) A Simple, Rapid Technique for Determination of the Effects of Chemotherapeutic Agents on Mammalian Cell Cycle Traverse. Cancer Research, 32, 309-316.
[127] Paoletti, C., Lesca, C., Cros, S., Mahy, C. and Auclairs, C. (1979) Ellipticine and Derivateves Induce Breakage of L1210 Cells DNA in Vitro. Biochemical Pharmacology, 28, 345-350.
[128] Bhuyan, B.K., Faser, T.J. and Li, L.H. (1972) Cell Cycle Phase Specificity and Biochemical Effects of Ellipticine on Mammalian Cells. Cancer Research, 32, 2538-2544.
[129] Saucier, J.M., Festy, B. and Lepecq, J.B. (1971) The Change of Torsion of the DNA Helix Caused by Intercalation. II. Measurement of the Relative Change of Torsion Induced by Various Intercalating Drugs. Biochimie, 53, 973-980.
[130] Festy, B., Poisson, J. and Paolettic, C. (1975) A New DNA Intercalating Drug: Methoxy-9-Ellipticine to DNA. Cancer Research, 35, 71-76.
[131] Oster, J.B. and Creasey, W.A. (1981) Enhancement of Cellular Uptake of Ellipticine by Insulin Preincubation. European Journal of Cancer and Clinical Oncology, 17, 1097-1103.
[132] Ohnuma, T. and Holland, J.F. (1997) Nutritional Consequences of Cancer Chemo Therapy and Immunotherapy. Cancer Research, 37, 2395-2406.
[133] Shamberger, R.C., Brennan, M.F., Goodgame, J.T., Lowry, S.F., Maher, M.M., Wesley, R.A. and Pizzo, P.A. (1984) A Prospective Randomized Study of Adjuvant Parenteral Nutrition in the Treatment of Sarcomas: Results of Survival and Metabolic Studies. Surgery, 96, 1-13.
[134] Peacock, J.L., Gorschboth, C.M. and Northon, J.A. (1987) Impact of Insulin on Doxorubicin Induced Rat Host Toxicity and Tumor Regression. Cancer Research, 47, 4318-4322.
[135] Chabner, B.A. and Meyers, C.E. (1985) Clinical Pharmacology of Cancer Chemo Therapy. In: DeVita, V.T., Hellman, S. and Rosenberg, S.A., Eds., Cancer, Principles and Practice of Oncology, J.B. Lippincott Company, Philadelphia, 312.
[136] Kafka, M.S. (1974) The Effect of Insulin on the Permeability of Phosphatidyl Choline Bimolecular Membranes to Glucose. Journal of Membrane Biology, 18, 81-94.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.